Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Evotec AG ( (EVO) ) has shared an announcement.
On January 1, 2026, Evotec SE announced the appointment of Dr. Sarah Fakih as Executive Vice President, Head of Global Communications and Investor Relations, a newly created role that integrates the company’s communications and investor relations functions. Reporting directly to CEO Dr. Christian Wojczewski and succeeding departing Investor Relations and ESG head Volker Braun, Dr. Fakih brings more than 15 years of life sciences experience and a capital markets and corporate messaging track record from senior roles at QIAGEN, MorphoSys and CureVac, a move aimed at sharpening Evotec’s strategic messaging, improving stakeholder engagement and reinforcing alignment around its scientific leadership and value creation narrative.
The most recent analyst rating on (EVO) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.
Spark’s Take on EVO Stock
According to Spark, TipRanks’ AI Analyst, EVO is a Neutral.
Evotec AG’s overall stock score is primarily impacted by its weak financial performance and concerning valuation metrics. The company is struggling with profitability and cash flow issues, reflected in a negative P/E ratio and lack of dividend yield. Technical analysis shows a bearish trend, further weighing on the score. Despite some positive developments from the earnings call, such as growth in the Biologics segment and strategic partnerships, these are not enough to offset the significant financial challenges.
To see Spark’s full report on EVO stock, click here.
More about Evotec AG
Evotec SE is a Germany-based life science company focused on pioneering drug discovery and development by integrating breakthrough science with AI-driven innovation and advanced technologies. Its expertise spans small molecules, biologics, cell therapies and related modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modelling. The company serves all of the top 20 pharmaceutical groups, more than 800 biotechs, academic institutions and other healthcare stakeholders through flexible partnering models, offering services from standalone research to fully integrated R&D programmes and long-term strategic collaborations, with a strong portfolio of over 100 proprietary R&D assets across oncology, cardiovascular and metabolic diseases, neurology and immunology.
Average Trading Volume: 129,887
Technical Sentiment Signal: Sell
Current Market Cap: $1.14B
Learn more about EVO stock on TipRanks’ Stock Analysis page.